2024-10-26 - Analysis Report
## Johnson & Johnson (JNJ) Stock Analysis Report

**Company Overview:** Johnson & Johnson is a multinational pharmaceutical, medical device, and consumer packaged goods company.

**Performance vs S&P 500 (VOO):**

* **Cumulative Return:** JNJ: 36.59%, VOO: 135.48%.
* **Relative Performance:** JNJ is lagging behind VOO by a significant margin (-98.89%). This signifies that JNJ's performance has been significantly weaker than the broader market.
* **Relative Divergence:** The current relative divergence of -98.89% implies that JNJ's performance has been in the bottom 5.74% of its historical range against the VOO.

**Recent Price Movement:**

* **Closing Price:** $163.67 (Last Market: $160.77).
* **Moving Averages:**
    * 5-Day Moving Average: $164.01
    * 20-Day Moving Average: $162.26
    * 60-Day Moving Average: $162.73

**Technical Indicators:**

* **RSI:** 61.51 - Indicates that the stock is currently in the overbought territory, suggesting a potential near-term pullback.
* **PPO:** 0.19 - A positive value indicates a potential for continued price appreciation, but the relatively low value suggests a moderate upward momentum.
* **Delta_Previous_Relative_Divergence:** +0.4 - Suggests short-term upward price movement.
* **Expected Return:** 0.0% - Based on historical performance and current market conditions, JNJ is not expected to outperform the S&P 500 significantly in the long term (2+ years).

**Recent Earnings and Outlook:**

| Date        | EPS    | Revenue      |
|-------------|--------|--------------|
| 2024-10-23 | 1.12   | $22.47 Billion |
| 2024-07-25 | 1.95   | $22.45 Billion |
| 2024-05-01 | 1.35   | $21.38 Billion |
| 2024-02-16 | 1.68   | $21.39 Billion |
| 2023-10-27 | 10.32  | $21.35 Billion |

The most recent earnings report (2024-10-23) indicated an EPS of 1.12, exceeding analyst expectations by a small margin. The revenue was slightly higher than the previous quarter, but remained consistent with the recent trend.

**News and Recent Events:**

* **Earnings News:** Check Shacknews and other financial news outlets for the latest earnings report analysis and commentary.
* **Analyst Opinions:** Refer to FINBOLD and other financial websites for recent analyst ratings and price targets. They typically provide a summary of analyst sentiment and performance highlights.

**Overall Analysis:**

Johnson & Johnson's performance has been lagging behind the broader market, particularly the S&P 500, with a significant relative divergence compared to its historical performance. While recent earnings have exceeded expectations, the company's overall growth and long-term prospects remain uncertain. Technical indicators suggest a potential for near-term consolidation or pullback, as the stock is currently in overbought territory. Based on current market conditions and historical performance, JNJ is not expected to significantly outperform the S&P 500 in the long term. 

**Disclaimer:** This analysis is based on publicly available information and should not be considered investment advice. Investors should conduct their own thorough research and consult with a financial advisor before making any investment decisions. 
